Robert Bruce Cuts Abbott Laboratories Stake 14.95%, AbbVie at 8.68%
Value investor Robert Bruce cut his Abbott Laboratories stake by 20,000 shares, a 14.95% reduction that trimmed his Q4 2025 portfolio by 0.83%. AbbVie represented 8.68% of the fund’s assets alongside AerCap, Allstate and NextEra Energy holdings.
1. Portfolio Adjustment
In the fourth quarter of 2025, Robert Bruce reduced his position in Abbott Laboratories by 20,000 shares, representing a 14.95% decrease in share count. This move lowered the fund’s overall portfolio exposure by 0.83%, reflecting a tactical repositioning among Bruce & Co’s equity holdings.
2. Performance Metrics
Abbott Laboratories shares traded at an average price of $127.30 during the quarter. Over the past three months, the stock has fallen 12.39% and is down 9.61% year-to-date, highlighting recent market headwinds.
3. Portfolio Composition
As of Q4 2025, the Bruce Fund held 39 stocks across nine industries, with AbbVie comprising 8.68% of assets, followed by 8.18% in AerCap, 8.10% in Allstate and 7.72% in NextEra Energy. The fund favors small- and mid-cap opportunities but selectively includes large-cap names.
4. Investment Strategy
Bruce & Co focuses on long-term value investments, often targeting distressed companies trading at discounts. The fund also allocates to high-yield and distressed debt, and U.S. government securities when equity opportunities are limited.